keyword
https://read.qxmd.com/read/36751210/incidental-splenic-marginal-zone-lymphoma-with-extreme-macrocytosis-after-hydroxyurea-use-a-case-report
#1
Kinza Sultan, Sarala Kal, Andrew Wasson, Farbod Farmand
Splenic marginal zone lymphoma (SMZL) is a low-grade mature B-cell lymphoma that typically presents in the form of splenomegaly and lymphocytosis. The diagnosis is traditionally made through splenic histology, the presence of circulating villous lymphocytes, or bone marrow biopsy. Its treatment can be in the form of chemotherapy, such as rituximab, or active surveillance. This case presentation discusses a 76-year-old female with a long history of hydroxyurea use for an unknown reason presenting with atypical symptoms requiring bone marrow biopsy to diagnose SMZL...
January 2023: Curēus
https://read.qxmd.com/read/36485086/management-of-marginal-zone-lymphomas
#2
JOURNAL ARTICLE
Michele Merli, Luca Arcaini
Marginal zone lymphomas (MZLs) represent about 7% of B-cell non-Hodgkin lymphomas and include 3 different subtypes-namely, extranodal (EMZL), nodal, and splenic (SMZL). The initial assessment requires specific diagnostic and staging procedures depending on organ-related peculiarities. In particular, although positron emission tomography/computed tomography was not initially recommended, recent data have reassessed its role in the routine staging of MZL, especially when only localized treatment is planned or there is a suspicion of histologic transformation...
December 9, 2022: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/35663281/immunotherapy-in-indolent-non-hodgkin-s-lymphoma
#3
JOURNAL ARTICLE
Ghid Amhaz, Ali Bazarbachi, Jean El-Cheikh
Treatment of non-Hodgkin lymphoma (NHL) in general has improved over the years with the emergence of the monoclonal antibodies (MAB) therapy. NHL is divided into B cell NHL and T cell NHL. Treatment of NHL was based on the subtype of NHL and its staging. NHL is divided into aggressive and indolent NHL (iNHL). Subtypes of iNHL include: Follicular lymphoma (FL), Marginal zone lymphoma (MZL), Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL), Gastric mucosa-associated lymphoid tissue (MALT) lymphoma, Lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, Nodal marginal zone lymphoma (NMZL), Splenic marginal zone lymphoma (SMZL)...
2022: Leukemia Research Reports
https://read.qxmd.com/read/34940070/a-review-on-splenic-diffuse-red-pulp-small-b-cell-lymphoma
#4
REVIEW
Elif Yilmaz, Arashpreet Chhina, Victor E Nava, Anita Aggarwal
Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is a rare disease, representing <1% of all non-Hodgkin lymphomas (NHL). The most common clinical manifestations include splenomegaly, lymphocytosis, and hemocytopenia. A diagnosis of SDRPL can be challenging, as it shares multiple clinical and laboratory features with splenic marginal zone lymphoma (SMZL), hairy cell leukemia (HCL), and HCL variant (HCL-v). Obtaining splenic tissue remains the gold standard for diagnosis. In the cases where splenic tissue is not available, diagnosis can be established by a review of peripheral blood and bone marrow studies...
December 6, 2021: Current Oncology
https://read.qxmd.com/read/34786250/hepatic-infiltration-by-splenic-marginal-zone-lymphoma-in-a-patient-with-cured-hepatitis-c
#5
Leonor Silva, Mafalda Alpoim, Ana Ribeiro, Pedro Caiano Gil, Rute Lopes Caçola
Splenic marginal zone lymphoma (SMZL) accounts for only 1-2.7% of all lymphomas. Almost all patients have bone marrow (BM) involvement but only one-third has liver involvement. The higher prevalence of hepatitis C virus (HCV) infection in these patients has led to the hypothesis of viral involvement in lymphomagenesis. In this report, we present a case of a 48-year-old woman, with cured hepatitis C, presenting with fever, weight loss, nausea, abdominal pain, and jaundice. She had leucocytosis with lymphocytosis, a progressively worsening cytocholestasis, and hepatosplenomegaly...
October 2021: Curēus
https://read.qxmd.com/read/34519021/clinico-biological-features-and-outcome-of-patients-with-splenic-marginal-zone-lymphoma-with-histological-transformation
#6
JOURNAL ARTICLE
Gabriela Bastidas-Mora, Sílvia Beà, Alba Navarro, Eva Gine, Dolors Costa, Julio Delgado, Tycho Baumann, Laura Magnano, Alfredo Rivas-Delgado, Neus Villamor, Dolors Colomer, Mónica Lopez-Guerra, María Rozman, Olga Balagué, Daniel Martínez, Maria Joao Baptista, Lourdes Escoda, Miguel Alcoceba, Margarita Blanes, Fina Climent, Elías Campo, Andrew Wotherspoon, Armando López-Guillermo, Estella Matutes
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0·05)...
January 2022: British Journal of Haematology
https://read.qxmd.com/read/34326035/clinical-characteristics-treatment-and-evolution-of-splenic-and-nodal-marginal-zone-lymphomas-retrospective-and-multicentric-analysis-of-portuguese-centers
#7
MULTICENTER STUDY
Catarina Dantas Rodrigues, Rita Pinho Peixeiro, Diana Viegas, Pedro Chorão, M Eduarda Couto, Cátia Lino Gaspar, João Paulo Fernandes, Daniela Alves, Lídia Alves Ribeiro, Pedro de Vasconcelos M, Ana Luísa Tomé, Margarida Badior, Henrique Coelho, Fernando Príncipe, Sérgio Chacim, Maria Gomes da Silva, Rita Coutinho
INTRODUCTION: Treatment of Splenic (SMZL) and Nodal (NMZL) Marginal Zone Lymphoma is not consensual. Histologic transformation (HT) to aggressive lymphoma is a poorly understood event, with an unfavorable outcome. OBJECTIVES: Describe the clinical characteristics, treatment, outcomes and incidence of HT. METHODS: Characteristics of patients with SMZL and NMZL consecutively diagnosed in 8 Portuguese centers were retrospectively reviewed. Endpoints were overall survival (OS), time to first systemic treatment (TTFST), frequency of HT and time to transformation (TTT)...
November 2021: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/34135652/emergency-splenectomy-in-a-patient-with-splenic-marginal-zone-lymphoma-acute-portal-vein-thrombosis-and-chronic-viral-hepatitis-b
#8
Radmila Karpova, Andrey Gorbunov, Marina Mnatsakanyan, Aleksandr Pogromov, Irina Sokolova, Yuliya Shumskaya, Ksenia Russkova, Kirill Chernousov, Daria Momatyuk
Splenic marginal zone lymphoma (SMZL) is a type of non-Hodgkin's lymphoma (NL) that occurs in 2 out of 100 cases and is more common in women aged >60 years. A sluggish, asymptomatic course of the disease does not exclude transformation into a malignant form that occurs in 25% of patients with SMZL. Another equally important sign of an NL is thrombosis that occurs in 3.6% to 17.1% of the cases. In this report, we present a case of emergency splenectomy in a patient owing to difficulties in the diagnosis of SMZL, rapid onset of acute portal vein thrombosis, and the fulminant enlargement of the spleen accompanied by an increased risk of its rupture...
2021: Journal of Blood Medicine
https://read.qxmd.com/read/33829216/epidemiology-of-marginal-zone-lymphoma
#9
JOURNAL ARTICLE
James R Cerhan, Thomas M Habermann
In 2016 there were an estimated 7,460 newly diagnosed patients with marginal zone lymphoma (MZL) in the US, which comprised 7% of all mature non-Hodgkin lymphomas (NHL). Based on data from the US SEER-18 program from 2001-2017, the age-standardized incidence rate for MZL was 19.6 per 1,000,000 person-years; 9% of MZL cases were splenic MZL (SMZL), 30% nodal MZL (NMZL), and 61% extranodal MZL (EMZL) of mucusa-associated lymphoid tissue (MALT). Incidence rates were slightly higher in men for SMZL and NMZL, but similar for EMZL, and increased steeply with age for all MZL subtypes...
March 2021: Annals of Lymphoma
https://read.qxmd.com/read/33004051/splenic-marginal-zone-lymphoma-a-case-report-and-literature-review
#10
REVIEW
Shiyu Zhang, Zefeng Xuan, Liang Zhang, Jiahua Lu, Penghong Song, Shusen Zheng
BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a rare non-Hodgkin lymphoma, and much little is known about its clinical characteristics and management strategies. Here we present a case of SMZL and review relevant literature to provide a better recognition of this disease entity. CASE PRESENTATION: A 49-year-old Chinese female was admitted to our hospital with complaints of abdominal distension and acid reflux. Physical examinations and imaging investigations suggested the presence of splenomegaly...
October 1, 2020: World Journal of Surgical Oncology
https://read.qxmd.com/read/32879838/guillain-barre-syndrome-and-syndrome-of-inappropriate-antidiuretic-hormone-siadh-secretion-as-paraneoplastic-syndromes-in-splenic-marginal-b-cell-non-hodgkins-lymphoma-a-rare-presentation
#11
Madhuri Patil, Vijayadershan Muppidi, Sreenath Meegada, Keanan T Dowell, Joe D Bowers
Splenic marginal zone lymphoma (SMZL), a rare sub-type of non-Hodgkin lymphoma (NHL) presents with abdominal discomfort, lymphocytosis, cytopenias along with B symptoms including fatigue, night sweats, night fevers, weight loss. NHLs rarely present with paraneoplastic neurological syndromes like Guillain-Barre (GB) syndrome, myelopathy causing paraplegia, chorea, neuromyotonia, vasculitic neuropathy and dermatomyositis. Here, we present a 85-year old caucasian lady presenting with GB syndrome and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) who eventually got diagnosed with SMZL...
August 30, 2020: Curēus
https://read.qxmd.com/read/32746790/risk-adapted-approach-how-to-treat-splenic-marginal-zone-lymphoma-in-resource-poor-settings-the-real-life-experience-of-a-brazilian-cancer-treatment-center
#12
JOURNAL ARTICLE
Luís Alberto de Pádua Covas Lage, Felipe Faganelli Caboclo Dos Santos, Débora Levy, Frederico Rafael Moreira, Samuel Campanelli Freitas Couto, Hebert Fabrício Culler, Renata de Oliveira Costa, Vanderson Rocha, Juliana Pereira
BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a rare lymphoid B-cell malignant neoplasm with primary involvement of the spleen. It is a chronic disease, of indolent behavior and prolonged survival. However, 25% of cases have higher biological aggressiveness, propensity for histological transformation to high grade B-cell non-Hodgkin lymphoma and shortened survival. Recognition of these cases of reserved outcome is important for selecting a risk-adapted therapeutic approach in a resource-poor settings...
August 3, 2020: BMC Cancer
https://read.qxmd.com/read/32703751/prognostic-value-of-18-f-fdg-pet-ct-metabolic-parameters-in-splenic-marginal-zone-lymphoma
#13
JOURNAL ARTICLE
Domenico Albano, Luca Camoni, Raffaele Giubbini, Francesco Bertagna
INTRODUCTION: Splenic marginal zone lymphoma (SMZL) is an indolent non-Hodgkin lymphoma usually with a good prognosis, but no clear metabolic behavior at fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). The aim of our analysis was to investigate the prognostic role of baseline 18F-FDG PET/CT parameters in SMZL. MATERIALS AND METHODS: We retrospectively included 42 patients who received 18F-FDG-PET/CT before any treatments, and PET images were evaluated visually and semi-quantitatively by measuring lesion to liver (L-L) maximum standardized uptake volume (SUVmax) ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), metabolic tumor volume, and total lesion glycolysis...
November 2020: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/32594531/bendamustine-rituximab-regimen-in-untreated-indolent-marginal-zone-lymphoma-experience-on-65-patients
#14
JOURNAL ARTICLE
Alice Morigi, Lisa Argnani, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Vittorio Stefoni, Paolo Elia Coppola, Matteo Carella, Beatrice Casadei, Elena Sabattini, Michele Cavo, Pier Luigi Zinzani
First line therapy of patients with marginal zone lymphomas (MZL) is not well established and various regimens with chemo-immunotherapy can be used. Rituximab plus bendamustine (BR) is an effective and manageable treatment option for patients affected by indolent non-Hodgkin lymphoma. The aim of this monocentric retrospective study was to analyze the effectiveness and safety of the use of BR regimen in MZL patients in first line in daily clinical practice. The treatment schedule was rituximab at the dose of 375 mg/m2 on day 1 of each cycle and bendamustine at the dose of 90 mg/m2 on day 2 and 3, every 28 days for a maximum of 6 cycles...
October 2020: Hematological Oncology
https://read.qxmd.com/read/32565679/rare-causes-of-isolated-and-progressive-splenic-lesions-challenges-in-differential-diagnosis-evaluation-and-treatment-of-primary-splenic-lymphomas
#15
Ryan B Sinit, Russell K Dorer, John Paul Flores, David M Aboulafia
The spleen is among the most common extranodal sites for Hodgkin and non-Hodgkin lymphomas (NHLs); however, among lymphomas arising from the spleen, primary splenic lymphomas (PSLs) are rare. The group of PSLs includes primary splenic diffuse large B-cell lymphoma (PS-DLBCL), splenic red pulp small B-cell lymphoma, splenic marginal zone lymphoma (SMZL), and a splenic hairy cell leukemia variant. Delineating between the PSL variants can be challenging, especially as fine-needle aspirate and core needle biopsy of the spleen are not routinely offered at most medical centers...
2020: Clinical Medicine Insights. Blood Disorders
https://read.qxmd.com/read/32457837/identification-of-a-splenic-marginal-zone-lymphoma-signature-preliminary-findings-with-diagnostic-potential
#16
JOURNAL ARTICLE
Jacob E Robinson, Timothy C Greiner, Alyssa C Bouska, Javeed Iqbal, Christine E Cutucache
Splenic marginal zone lymphoma (SMZL) is a rare, indolent non-Hodgkin's lymphoma that affects 0. 13 per 100,000 persons annually. Overall survival of SMZL is estimated to reach 8-11 years in most cases, but up to 30% of SMZL cases develop aggressive presentations resulting in greatly diminished time of survival. SMZL presents with a very heterogeneous molecular profile, making diagnosis problematic, and accurate prognosis even less likely. The study herein has identified a potential diagnostic gene expression signature with highly specific predictive utility, coined the SMZL-specific Gene Expression Signature (SSGES)...
2020: Frontiers in Oncology
https://read.qxmd.com/read/32158587/successful-surgical-removal-of-the-largest-known-spleen
#17
David J Hall, Nam H Dang, Christiana M Shaw
BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a rare subtype of non-Hodgkin lymphoma that typically presents with symptomatic splenomegaly. The optimal treatment of SMZL not well established. Case Presentation. A 44-year-old man with a history of low-grade B-cell lymphoproliferative disorder previously treated with chemotherapy presented with a three-month history of rapidly enlarging abdominal girth. He was found to have large symptomatic splenomegaly by computed tomography. After workup, he underwent preoperative angioembolization of the splenic artery followed by successful splenectomy...
2020: Case Reports in Surgery
https://read.qxmd.com/read/32151046/cerebral-hsv-1-vasculitis-as-a-fatal-complication-of-immunosuppression-in-non-hodgkin%C3%A2-s-lymphoma-a-case-report-and-review-of-the-literature
#18
Raffaele Nardone, Luca Carnicelli, Francesco Brigo, Slaven Pikija, Larissa Hauer, Johann Sellner
Patients with lymphoma are predisposed to infection because of the immunocompromised state related to the disease itself and as a consequence of chemo-/radiotherapy. Here, we report a case of Herpes-simplex virus encephalitis (HSE) in an immunosuppressed patient with splenic marginal zone lymphoma (SMZL), a rare indolent variant of non-Hodgkin´s lymphoma (NHL). The course was complicated febrile neutropenia and HSV-1-related cerebral vasculitis causing progressive ischemic stroke. This case illustrates the expanding spectrum of atypical clinical and radiological manifestations of HSE in patients treated with myelotoxic drugs...
March 5, 2020: Pathogens
https://read.qxmd.com/read/31892196/splenectomy-in-lymphoproliferative-disorders-a-single-eastern-european-center-experience
#19
JOURNAL ARTICLE
Minodora Onisâi, Ana-Maria Vlădăreanu, Adriana Nica, Andreea Spînu, Mihaela Găman, Horia Bumbea, Irina Voican, Iuliana Iordan, Adrian Alexandru, Mihnea Zdrenghea, Daniela Gheorghita, Sebastian Grădinaru
Background and Objectives: Hematological malignancies are usually systemic diseases of life-threatening impact, and frequently require prompt and energetic therapeutic intervention. Due to systemic involvement, the role of surgery is generally limited to diagnostic approaches, and it is very rarely employed as a therapeutic modality. Splenectomy represents an exception to this paradigm, being used both as a diagnostic and tumor debulking procedure, notably in splenic lymphomas. Materials and Methods: We investigated the role of splenectomy in a single center prospective study of splenectomy outcome in patients with splenic involvement in the course of lymphoproliferative disorders...
December 27, 2019: Medicina
https://read.qxmd.com/read/31619091/contemporary-management-of-nodal-and-primary-splenic-marginal-zone-lymphoma
#20
REVIEW
Lori A Leslie, Tatyana A Feldman, Ann McNeill, Mary Timberg, Hoshiyuki Iida, Andre H Goy
Introduction : Marginal zone lymphoma (MZL) accounts for approximately 10% of all cases of non-Hodgkin lymphoma and includes 3 clinically distinct subtypes: extranodal (MALT), splenic (SMZL), and nodal (NMZL). Though commonly grouped in trials of iNHL the clinical behavior, molecular features, and response to therapy of MZL is distinct from other iNHL subtypes and varies among MZL subtypes. Areas covered : This review focuses on the contemporary management of NMZL and SMZL. Treatment with monoclonal antibodies, chemoimmunotherapy, BTK inhibitors, PI3K/mTOR inhibitors, Bcl2 inhibitors, lenalidomide, and CAR-T cell therapy will be covered...
December 2019: Expert Review of Hematology
keyword
keyword
25672
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.